UPDATE: Raymond James Upgrades AmSurg Following Sheridan Health Acquisition

In a report issued Friday, Raymond James upgraded its rating of

from Market Perform to Strong Buy with a target price of $60. Analyst John W. Ransom has raised his estimates for AmSurg with its acquisition of Sheridan Health on Thursday. This merger should help boost organic and EPS growth, as well. Ransom also raised his EPS estimate from $2.77 to $3.15 for 2015. AmSurg will open Friday at $45.74.